October 6th 2024
Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.
September 18th 2024
More than 60% with Type 1 Diabetes Also Dealing with Overweight or Obesity, Study Finds
February 14th 2023An analysis of NHIS data from 2016-2021 indicates the rate of overweight or obesity among adults with type 1 diabetes was comparable to the rate among the general population, but these people were less likely to receive lifestyle recommendations from their providers.
New Therapies to Delay T1D Progression
February 8th 2023Robin S. Goland, MD, and Kimberly Simmons, MD, MPH/MSPH, provide insight on teplizumab, which was recently approved by the FDA, to delay the progression of type 1 diabetes, and they discuss the implications of autoantibody detection in patients.
Shared Decision-Making to Improve Long-Term Outcomes in Diabetes and Obesity
February 8th 2023Drs Diana Isaacs and Natalie Bellini highlight the need for engaging patients in shared decision-making and addressing social determinants of health in diabetes and obesity management in adults and pediatric patients.
Impact of New Treatment Approval and Other Advances on the Type 1 Diabetes Patient Community
February 6th 2023Sumita Singh, a T1D advocate, discusses with Diana Isaacs and Natalie Bellini how teplizumab and other advances are providing hope to the T1D community and talks about the challenges and needs of a diverse T1D patient population.
Challenges in Managing Type 1 Diabetes and Pressing Need for New Therapies
February 3rd 2023Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes
Diabetes Dialogue: FDA Clearance of Tidepool Loop
January 30th 2023In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.
FDA Approves Proclaim XR Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy
Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.
Tidepool Loop Mobile App Receives FDA Marketing Clearance
January 25th 2023Announced on January 24, the US FDA's marketing clearance for the Tidepool Loop mobile app allows for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons 6 years of age and older.